AbbVie's Rinvoq conquers Regeneron and Sanofi's Dupixent in eczema trial—again

For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown superior efficacy to Regeneron and Sanofi’s powerhouse Dupixent (dupilumab) in a head-to-head study in patients with atopic dermatitis (AD).